Oxurion NV — Director's Dealing 2023

Jun 12, 2023

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

June 12, 2023

Regulated Information

Leuven, BELGIUM, Boston, MA, US – June 12, 2023 – 8.00 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows:

Oxurion received a transparency notification on June 7, 2023, from Atlas Special Opportunities LLC indicating that as of May 30, 2023, it held 21,494,943 shares of the then outstanding 896,925,569 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities. See Annex 1.

Oxurion received a transparency notification on June 7, 2023, from Atlas Special Opportunities LLC indicating that as of June 1, 2023, it held 71,192,352 shares of the then outstanding 1,022,343,629 shares, and therefore crossed below the threshold (10%) by virtue of the acquisition and sale of voting securities. See Annex 2.

Oxurion received a transparency notification on June 9, 2023, from Atlas Special Opportunities LLC indicating that as of June 2, 2023, it held 19,092,777 shares of the then outstanding 1,022,343,629 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities. See Annex 3.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV	US
Tom Graney	Conway Communications
Chief Executive Officer	Mary T. Conway
Tel: +32 16 75 13 10	mtconway@conwaycommsir.com
tom.graney@oxurion.com
Michael Dillen
Chief Business Officer	ICR Westwicke
Tel: +32 16 75 13 10	Christopher Brinzey
michael.dillen@oxurion.com	Tel: +1 617 835 9304
	Chris.Brinzey@westwicke.com

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

________

FSMA FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
1) Status of the notification
Final
2) Issuer
Name OXURION Identification number 0881-620-924
3) Reason for the notification
Acquisition or disposal of voting securities or voting rights
Downward crossing of the lowest threshold
4) Notification by
A person that notifies alone
5) Persons subject to the notification requirement
Name	Address (for legal entities)
Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577
6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
Name	Address (for legal entities)
Please continue entering the information in part II concerning the persons referred to in Sections 5 and 6 D	Part II
7) Date on which the threshold is crossed
	30/05/2023 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
3
If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

896,925,569

Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	32.301.799	21,494,943		2.40%
	TOTAL	21,494,943	0	2.40%	0.00%

+

Start with "groups" of holders. Add subtotals with Thish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
							+
	TOTAL			0	0.00%

The totals will be updated once you have clicked on

TOTAL (A & B)			# of voting rights % of voting rights
	CALCULATE	21,494,943	2.40%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

12) In case of proxy voting for only one GM

Holder	will cease to hold / will hold again		(DD/MM/YYYY) voting rights as of
13) Additional information
Atlas Special Opportunities LLC held 45,289,855 shares in Oxurion NV on 30/05/2023 (= 5.05%).
On 30/5/2023 Atlas Special Opportunities L.C sold 23,794,912 shares in Oxurion NV, as a result of which its shares (n 2.40%).

	Done at New York
On		07/06/2023 (DD/MM/YYYY)
	Name & capacity Patrick Vance, proxyholder	Signature

Patrick Vance

ANNEX 2

FSMA FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
1) Status of the notification
Final
2) Issuer
Name OXURION ldentification number 0881-620-924
3) Reason for the notification
Acquisition or disposal of voting securities or voting rights
4) Notification by
A person that notifies alone
5) Persons subiect to the notification requirement
Name	Address (for legal entities)
Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577
6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
Name	Address (for legal entities)
Please continue entering the information in part II concerning the persons referred to in Sections 5 and 6	Part II
7) Date on which the threshold is crossed
	01/06/2023 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
10
	If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

1,022,343,629 Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	21,494,943	71.192.352		6.96%
TOTAL		71.192,352	0	6.96%	0.00%

+

Start with "groups" of holders. Add subtotals with 2, and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or leg

B) Equivalent financial instruments After the transaction # of voting rights
that may been the
Holders of equivalent
financial instruments Expiration date Type of financial instrument % of voting rights Settlement + TOTAL 0 0.00%

The totals will be updated once you have clicked on

TOTAL (A & B)			# of voting rights % of voting rights
	CALCULATE	71,192,352	6.96%

12) In case of proxy voting for only one GM

Holder	will cease to hold / will hold again	(DD/MM/YYYY) voting rights as of
13) Additional information
Atlas Special Opportunities LLC held 21,494,943 shares in Oxurion NV on 30/05/2023 (= 2.40%).
On: 3105/2022 Alas Special Opportunities LLC reares and subsequently sold 34,70,011 shares as a result of which its sharending increased on 12,200,900 shares (= 1.97%), On 01/06/2023 Alas Special Opportunities LLC sold 41,018,640 shares, as a result of which its shareholding decreased to 71,192,352 shares (= 6.96%).

	Done at New York
On		07/06/2023 (DD/MM/YYYY)
	Name & capacity Patrick Vance, proxyholder

Signature Patrick Vance

ANNEX 3

FSMA FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
1) Status of the notification
Final
2) Issuer
Name OXURION
ldentification number 0881-620-924
3) Reason for the notification
Acquisition or disposal of voting securities or voting rights Downward crossing of the lowest threshold
4) Notification by
A person that notifies alone
5) Persons subject to the notification requirement
Name	Address (for legal entities)
Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577
6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
Name	Address (for legal entities)
Please continue entering the information in part II concerning the P persons referred to in Sections 5 and 6	Part II
7) Date on which the threshold is crossed
	02/06/2023 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
	3
	If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

1,022,343,629

Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	71,192,352	19,092,777		1.87%
	TOTAL	19,092,777		1.87%

[
	other

Start with "groups" of holders. Add subtotals with 22, and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or le

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial Instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the Instrument is exercised	% of voting rights	Settlement
							+
	TOTAL

The totals will be updated once you have clicked on

TOTAL (A & B)			# of voting rights % of voting rights
	CALCULATE	19,092,777	1.87%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

12) In case of proxy voting for only one GM

			(DD/MM/YYYY)
Holder	will cease to hold / will hold again	voting rights as of

13) Additional information

Atlas Special Opportunities LLC held 71,192,352 shares in Oxurion NV on 01/06/2023 (= 6.96%).
On 1206/2023 Atas Seedal Open in the LC sold S2,099,575 shares, as a result of which its shareholding decreased b 19,092,77 shares = 1,87%). On US\$69/223 Allas Special Oportu 19,092,777 shares, as a result of which its shareholding decreased to 0 shares (= 0.00%).

Signature Patrick Vance

Attachments

• EN
• NL